Icon

HEPZATO (NDA201848)- (EQ 50MG BASE/VIAL)

MELPHALAN HYDROCHLORIDE DELCATH SYSTEMS INC
EQ 50MG BASE/VIAL
No Yes
2034-Sep-17 Expired
None 2026-Aug-14
None No
HEPZATO is an alkylating drug indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 50MG BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.